16-gene recurrence score for high-risk kidney cancer offers prognostic value

Results from a phase III trial presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting held in Chicago last week confirmed the prognostic value of a 16-gene recurrence score (RS) in patients with high-risk renal cell carcinoma (RCC) undergoing adjuvant sunitinib therapy. Though the score cannot yet be used to select patients […]

read more

Biomarkers predict kidney cancer treatment outcomes

Two recent studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago this week, suggest that levels of a protein called hepatocyte growth factor (HGF) in the blood, and certain changes (mutations) in the genes called┬áBAP1 and PBRM1 in kidney cancer tumours are promising biomarkers for the prediction of survival […]

read more

Biomarkers for kidney cancer: A review of the challenges and evidence

The following review article summarises the work completed to date regarding the search for biomarkers for renal cell carcinoma (RCC)┬áto better guide treatment and improve outcomes, while limiting side effects. The role of biomarkers in RCC is controversial, due to uncertainty about which biomarker is the most beneficial. There is also debate about how often […]

read more

Potential novel biomarker for kidney cancer

A novel potential biomarker for renal cell carcinoma (RCC) tumours has been discovered. Levels of a protein called progesterone receptor membrane component 1 (PGRMC1) have been shown to be raised in a number of different human cancers; however, the roles of PGRMC1 in renal cancer are not clear and merit further study. In the current […]

read more

Biomarkers predict response to TKI therapy for kidney cancer patients

A recent study published last month provides evidence that the presence of small pieces of genetic material, called microRNAs (miRNAs), in the cancer cells can predict response to treatment with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC). The miRNAs define patients refractory to TKI therapy who have a poor prognosis. […]

read more
Showing 81 to 85 of 85 results